TELOMELYSIN Trademark

Trademark Overview

On Wednesday, May 25, 2022, a trademark application was filed for TELOMELYSIN with the United States Patent and Trademark Office. The USPTO has given the TELOMELYSIN trademark a serial number of 79343439. The federal status of this trademark filing is REGISTERED as of Tuesday, February 20, 2024. This trademark is owned by Oncolys BioPharma Inc.. The TELOMELYSIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of cancer; veterinary preparations for the treatment of cancer, and sanitary preparations for medical purposes
telomelysin

General Information

Serial Number79343439
Word MarkTELOMELYSIN
Filing DateWednesday, May 25, 2022
Status700 - REGISTERED
Status DateTuesday, February 20, 2024
Registration Number7307222
Registration DateTuesday, February 20, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 5, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of cancer; veterinary preparations for the treatment of cancer, and sanitary preparations for medical purposes

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, June 24, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameOncolys BioPharma Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP
Party NameOncolys BioPharma Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP
Party NameOncolys BioPharma Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events

Event DateEvent Description
Tuesday, June 28, 2022APPLICATION FILING RECEIPT MAILED
Thursday, June 23, 2022SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Friday, June 24, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 14, 2023ASSIGNED TO EXAMINER
Saturday, March 18, 2023NON-FINAL ACTION WRITTEN
Sunday, March 19, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, May 5, 2023REFUSAL PROCESSED BY MPU
Friday, May 5, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, June 6, 2023REFUSAL PROCESSED BY IB
Thursday, October 26, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, October 26, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, October 27, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 30, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 15, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, November 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, November 15, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, December 5, 2023PUBLISHED FOR OPPOSITION
Wednesday, November 29, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, November 29, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, December 5, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, December 18, 2023NOTIFICATION PROCESSED BY IB
Monday, December 18, 2023NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, February 20, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, February 20, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, May 21, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, July 2, 2024FINAL DISPOSITION PROCESSED
Wednesday, July 3, 2024FINAL DISPOSITION NOTICE SENT TO IB
Saturday, July 20, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, May 21, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

Related Keywords

telomelysin preparations treatment cancer purposes medical sanitary veterinary pharmaceutical